A simple tool can quickly provide patients, with a dementia diagnosis, with more clarity about their average life expectancy. This tool is developed by Radboud university medical center researchers, including epidemiologist Miriam Haaksma, in collaboration with colleagues from the Karolinska Institute in Sweden. It will help caregivers to plan the appropriate care, and to start talking about life expectancy. The results of the study were published in the scientific journal Neurology®.
The tool can be used for people with dementia who are diagnosed in primary care and in memory clinics. It can support physicians in discussing the sensitive topic of life expectancy with the patient and their family. Such a conversation can help in adequately planning the required care. Marcel Olde Rikkert, geriatrician in the Radboudumc and involved with the research: “This research provides new insight into the average life expectancy of patients with dementia as it brings different factors together. The tool demonstrates that there is a large variety of dementia and secondary diseases and consequently of prognoses. This means that the provision of personalized care remains of vital importance.
The tool combines age with other diseases
The below table outlines how the tool works. The Mini-Mental State Examination (MMSE) is a short questionnaire that is used when memory issues or dementia are suspected. The test provides an overview of someone’s cognitive skills. The Charlson Comorbidity Index shows how many other diseases a patient has. Dark green indicates a high 3-year survival rate, while dark purple indicates a low survival rate.
These tables illustrate the 3-year survival rate for people who are diagnosed with dementia in primary care (for instance by the GP). Dark green indicates a high survival rate, while dark purple indicates a low survival rate.
Swedish Dementia Register
The researchers, including Haaksma of Radboudumc, looked at the data of over 50,000 patients over the age of 65 for this research. These patients were registered in the Swedish Dementia Register “SveDem”, and were tracked between 2007 and 2015. This means that the tools are most applicable to Swedish healthcare. To use the tool in other countries, it must be tested whether it is also valid there. The relationship between mortality and gender, age, cognitive status, and other diseases has been repeatedly demonstrated, so it can be assumed that similar models can be used in other western European countries.
Different life expectancy for different types of dementia
In the Netherlands, about a quarter of a million people have some form of dementia. There is no cure for this disease at the moment. However, there are many types of dementia, and they develop differently in different individuals. Some can live with their disease for many years, while others have a type of dementia that progresses quicker. Epidemiologist Miriam Haaksma: “To allow for an adequate planning of healthcare, it is important to take the life expectancy of the patient into account. Previous research has shown that uncertainty about the progression of the disease can be a barrier for planning the required healthcare. To decrease this uncertainty for people with dementia, their relatives, and caregivers, we have visualized the survival rate in two graphic tables based on a number of easy to measure factors.
Related news items
Frank Walboomers 25-years work anniversary at Radboudumc17 September 2020
Frank Walboomers, associate professor at the research group Regenerative Biomaterials at the Dept. of Dentistry (theme Reconstructive & Regenerative Medicine), celebrated his 25th work anniversary at Radboudumc.read more
Tjitske Kleefstra appointed endowed professor of Clinical genetics and psychopathology of rare syndromes17 September 2020
Tjitske Kleefstra has been appointed endowed professor of Clinical genetics and psychopathology of rare syndromes at the department of Neurodevelopmental disorders, with effect from 1 September.read more
Annette Schenck appointed professor of Translational Genetics17 September 2020
Annette Schenck has been appointed professor of Translational Genetics at the department of Neurodevelopmental disorders, with effect from 1 August. The chair will bring together fundamental and translational research in the field of brain developmental disorders.read more
Centuries-old medicine reduces the risk of new cardiovascular disease in heart patients17 September 2020
Colchicine, an anti-inflammatory drug that has been used for gout for centuries, has been shown to prevent cardiovascular disease in patients who have had a heart attack or are suffering from narrowed coronary arteries. Results of the study are published in the New England Journal of Medicine.read more
Radboudumc does large-scale research on systemic sclerosis10 September 2020
In rare diseases, such as systemic sclerosis, it’s often difficult to conduct large-scale research. Rheumatologist Madelon Vonk has managed to follow enough patients with systemic sclerosis for years. The results of her research have been published in BMJ Annal of the Rheumatic Diseases.read more